Research Article
Analysis of Serum IgG1 to Predict Progression and Therapeutic Effect in Patients with Multiple Myeloma
Table 4
Concentration of serum and urine light chains in patients with multiple myeloma.
| | | Decreased N (%) | Normal N (%) | Increased N (%) |
| | Serum κ-LC (N = 560; range: 629–1350 mg/dL) | 252 (45.00) | 154 (27.50) | 154 (27.50) | | Serum λ-LC (N = 560; range: 313–723 mg/dL) | 240 (42.86) | 172 (30.71) | 148 (26.43) | | Urine κ-LC (N = 543; range: <1.85 mg/dL) | — | 189 (34.87) | 353 (65.13) | | Urine λ-LC (N = 543; range: <5 mg/dL) | — | 381 (70.30) | 161 (29.70) |
|
|
